Phathom Preps for Wall Street Spotlight with Strong Sales Momentum

FLORHAM PARK, NJ – February 23, 2026 – Phathom Pharmaceuticals is preparing for a pivotal March, with its management team slated to present the company’s story at a trio of high-profile investor conferences. The announcement comes as the biopharmaceutical firm rides a wave of commercial momentum, armed with robust sales figures for its flagship gastrointestinal (GI) drug, VOQUEZNA, and a clear line of sight toward profitability.

In a formal announcement, the company confirmed its participation in the TD Cowen 46th Annual Health Care Conference in Boston, the Jefferies Biotech on the Beach Summit, and the Barclays 28th Annual Global Healthcare Conference, both in Miami. These events provide a critical platform for Phathom to engage directly with institutional investors, analysts, and industry stakeholders, laying out its strategic vision and financial progress.

While such conference circuits are standard for publicly traded biotech firms, Phathom’s upcoming presentations are particularly timely. The company is scheduled to report its full fourth-quarter and year-end 2025 results just days before the first conference, giving its executive team a fresh set of impressive data points to anchor their narrative. This strategic timing allows management to move beyond projections and present a compelling case built on tangible achievements.

The VOQUEZNA Growth Engine

The centerpiece of Phathom's story is the remarkable commercial ascent of VOQUEZNA (vonoprazan). As a first-in-class potassium-competitive acid blocker (PCAB), the drug represents a significant innovation in a market long dominated by proton pump inhibitors (PPIs) like Prilosec and Nexium. Approved for treating various GERD conditions and H. pylori infections, VOQUEZNA offers a differentiated mechanism that has resonated with prescribers.

Recent performance metrics underscore this success. The company recently announced that it has already surpassed one million prescriptions dispensed in the U.S. since the product's launch. This milestone is the culmination of sustained, impressive growth. In the third quarter of 2025 alone, approximately 221,000 VOQUEZNA prescriptions were filled, a 28% surge over the previous quarter. This followed sequential growth of 36% in the second quarter and 8% in the first quarter, demonstrating an accelerating adoption curve.

Fueling this growth is a refined commercial strategy. In mid-2025, Phathom pivoted its sales efforts to focus more intensely on gastroenterologists and other high-volume prescribers. This strategic shift from broad-based outreach to targeted engagement is designed to deepen relationships with specialists who treat the most complex GI cases and are most likely to adopt novel therapies. With over 29,300 unique healthcare providers already writing prescriptions and commercial insurance access covering over 120 million lives, the infrastructure for continued expansion is firmly in place.

A Disciplined Path to Profitability

For many investors in the biotech sector, the key question is not just about revenue growth, but the path to sustainable profitability. Phathom’s management has made this a core tenet of its corporate strategy, and it will be a central theme of their March presentations. The company has confidently guided that it expects to achieve operating profitability in the second half of 2026.

Crucially, Phathom asserts it can reach this milestone without needing to raise additional equity financing. This is a powerful message in a capital-intensive industry, signaling financial discipline and a strong belief in its cash flow generation. As of the end of 2025, the company held approximately $130 million in cash and cash equivalents. This financial stability is underpinned by a concerted effort to manage expenses.

After a period of heavy investment in the commercial launch, Phathom has streamlined its operations. Non-GAAP operating expenses, for example, saw a dramatic decrease from $86.1 million in the second quarter of 2025 to a more controlled $49.3 million in the third quarter. Preliminary estimates for the fourth quarter project these expenses to remain in the low-$50 million range, indicating that cost-saving measures have been successfully embedded into the company’s financial structure.

This combination of soaring revenues and disciplined spending is the formula investors will be keen to scrutinize. Preliminary fourth-quarter 2025 sales are expected to land between $57 million and $58 million, beating consensus estimates. Consequently, the company has raised its full-year 2025 revenue guidance to a range of $174.5 million to $175.5 million, providing a strong foundation for its 2026 profitability goal.

Securing the Future with Innovation

While the immediate focus is on the commercial success of VOQUEZNA, Phathom is also building a case for long-term value creation. The company's intellectual property provides a formidable moat, with VOQUEZNA holding New Chemical Entity (NCE) exclusivity through May 2032. This protection gives Phathom a long runway to maximize its market potential before facing generic competition, which is not anticipated until 2033 at the earliest.

Furthermore, the company is actively working to expand vonoprazan's therapeutic reach. In November 2025, Phathom initiated a Phase 2 clinical trial, pHalcon-EoE-201, to evaluate the drug as a potential treatment for eosinophilic esophagitis (EoE), a chronic inflammatory condition of the esophagus with significant unmet need. With topline data expected in 2027, this program represents a significant pipeline opportunity that could add another major indication to the VOQUEZNA label.

As Phathom's leadership team prepares for their fireside chat at the Barclays conference and company presentation at TD Cowen, they will be articulating a multi-faceted story. It is the story of a disruptive product successfully challenging an established market, a company executing a disciplined financial strategy to achieve profitability, and a vision for future growth through continued innovation. For Phathom Pharmaceuticals, the March presentations represent a crucial opportunity to prove that its strategic discipline and commercial momentum are building a sustainable leader in the gastrointestinal market.